Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4781823 | 1.00 | SLC6A3 (0.67) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL4781820 | 1.00 | SLC6A3 (0.67) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL3180497 | 0.82 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL3184955 | 0.81 | HIF1A (0.60) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL28321870 | 0.81 | MEN1 (0.53) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL20482078 | 0.80 | MEN1 (0.56) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL20482079 | 0.80 | MEN1 (0.56) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL3179208 | 0.80 | HIF1A (0.66) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20828152 | 0.78 | SLC6A2 (0.64) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL3179287 | 0.78 | SLC6A2 (0.64) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | SOSEI R & D LTD. (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | disclosed |
| EP-1993544-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102011-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | disclosed |
| EP-1328514-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SLC6A3 709/4885SLC6A2 445/4885SLC6A4 462/4885 |
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | HRH3, HRH2, HRH1 | SLC6A3 1982/4885SLC6A2 993/4885SLC6A4 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.